pyruvic acid has been researched along with HIV Coinfection in 10 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " BMS-488043 is an orally bioavailable AI that binds to gp120 of HIV-1 and abrogates its binding to CD4(+) lymphocytes." | 2.76 | In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. ( Alexander, L; Colonno, R; Eggers, B; Fan, L; Fang, H; Fang, J; Gong, YF; Grasela, D; Hanna, GJ; Kadow, J; Krystal, M; Langley, DR; Lin, PF; Nowicka-Sans, B; Wang, T; Zhang, S; Zhou, N, 2011) |
| " BMS-488043 was generally safe and well tolerated." | 2.76 | Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. ( Colonno, R; Grasela, DM; Hanna, GJ; Hellinger, JA; Krystal, M; Lalezari, J; Lin, P; Nettles, R; Persson, A; Wohl, DA, 2011) |
| " The first group (A) consisted of patients with presumed NRTI-related adverse events (n=21), the second group (B) consisted of patients without adverse events (n=28), the third group (C) were HIV-infected patients without antiretroviral therapy (n=6) and the last group (D) were healthy controls (n=12)." | 1.32 | Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. ( Koopmans, PP; ter Hofstede, HJ; Willems, HL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, T | 3 |
| Yin, Z | 1 |
| Zhang, Z | 1 |
| Bender, JA | 1 |
| Yang, Z | 2 |
| Johnson, G | 1 |
| Zadjura, LM | 1 |
| D'Arienzo, CJ | 1 |
| DiGiugno Parker, D | 1 |
| Gesenberg, C | 1 |
| Yamanaka, GA | 1 |
| Gong, YF | 2 |
| Ho, HT | 2 |
| Fang, H | 3 |
| Zhou, N | 3 |
| McAuliffe, BV | 1 |
| Eggers, BJ | 1 |
| Fan, L | 3 |
| Nowicka-Sans, B | 3 |
| Dicker, IB | 1 |
| Gao, Q | 1 |
| Colonno, RJ | 1 |
| Lin, PF | 3 |
| Meanwell, NA | 1 |
| Kadow, JF | 1 |
| Sun, Y | 1 |
| Zhu, Y | 1 |
| Hu, Y | 1 |
| McAuliffe, B | 1 |
| Rose, B | 1 |
| Kadow, J | 2 |
| Krystal, M | 3 |
| Alexander, L | 2 |
| Colonno, R | 3 |
| Zhang, S | 1 |
| Fang, J | 1 |
| Eggers, B | 1 |
| Langley, DR | 1 |
| Grasela, D | 1 |
| Hanna, GJ | 2 |
| Lalezari, J | 1 |
| Hellinger, JA | 1 |
| Wohl, DA | 1 |
| Nettles, R | 1 |
| Persson, A | 1 |
| Lin, P | 1 |
| Grasela, DM | 1 |
| Da, LT | 1 |
| Quan, JM | 1 |
| Wu, YD | 1 |
| ter Hofstede, HJ | 1 |
| Willems, HL | 1 |
| Koopmans, PP | 1 |
| Maagaard, A | 1 |
| Holberg-Petersen, M | 1 |
| Kvittingen, EA | 1 |
| Sandvik, L | 1 |
| Bruun, JN | 1 |
| Timmermans, EC | 1 |
| Tebas, P | 1 |
| Ruiter, JP | 1 |
| Wanders, RJ | 1 |
| de Ronde, A | 1 |
| de Baar, MP | 1 |
| McComsey, GA | 1 |
| Lo Re, V | 1 |
| O'Riordan, M | 1 |
| Walker, UA | 1 |
| Lebrecht, D | 1 |
| Baron, E | 1 |
| Mounzer, K | 1 |
| Frank, I | 1 |
| de Martino, M | 1 |
| Zammarchi, E | 1 |
| Filippi, L | 1 |
| Donati, MA | 1 |
| Mannelli, F | 1 |
| Galli, L | 1 |
| Vierucci, A | 1 |
3 trials available for pyruvic acid and HIV Coinfection
| Article | Year |
|---|---|
In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.
Topics: Amino Acid Sequence; Anti-HIV Agents; CD4 Antigens; Dose-Response Relationship, Drug; Double-Blind M | 2011 |
Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug | 2011 |
Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; Bone Density; DNA, Mitochondrial; Female; | 2008 |
7 other studies available for pyruvic acid and HIV Coinfection
| Article | Year |
|---|---|
Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug ca
Topics: Animals; Anti-HIV Agents; Cell Line; Drug Discovery; HIV Infections; HIV-1; Humans; Indoles; Models, | 2009 |
Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies.
Topics: Antibodies, Neutralizing; Drug Resistance, Viral; HIV Antibodies; HIV Envelope Protein gp120; HIV En | 2010 |
Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry.
Topics: CD4 Antigens; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Indo | 2011 |
Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers.
Topics: Adult; Anti-HIV Agents; DNA, Mitochondrial; Female; HIV Infections; HIV-1; Humans; Lactic Acid; Male | 2004 |
Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; DNA, Mitochondrial; Drug Monitoring; Female; HIV Infection | 2006 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mit | 2006 |
Redox potential status in children with perinatal HIV-1 infection treated with zidovudine.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Child; Child, Preschool; Female; HIV Infections; HIV-1; Humans | 1995 |